Intermittent fasting (IF) is increasingly recognized as an effective dietary intervention for slowing aging process and alleviating metabolic disturbances in multiple chronic diseases, especially in cardiovascular diseases (CVDs). Despite recent progress, the mechanisms behind its effects on cardiovascular health from the perspective of circadian rhythms are not yet fully understood. This review aims to explore the interaction between IF and circadian rhythms, focusing on their combined effects on cardiometabolic risks and cardiovascular outcomes. Evidence from animal models and clinical trials suggests that IF provides protective effects against cardiac damage and dysfunction. It is also indicated that IF influences key cardiometabolic risk factors, such as insulin sensitivity, inflammation, and lipid metabolism, by aligning with the intrinsic biological rhythms. Additionally, we discuss the therapeutic potential of IF in cardiovascular outcomes, particularly in individuals with circadian disruptions. This review also highlights future research directions to identify the most effective fasting protocols and assess the long-term cardiovascular benefits of IF in disease prevention and treatment.
With geroscience research evolving at a fast pace, the need arises for human randomized controlled trials to assess the efficacy of geroprotective interventions to prevent age-related adverse outcomes, disease, and mortality in normative aging cohorts. However, to confirm efficacy requires a long-term and costly approach as time to the event of morbidity and mortality can be decades. While this could be circumvented using sensitive biomarkers of aging, current molecular, physiological, and digital endpoints require further validation. In this review, we discuss how collecting real -world evidence (RWE) by obtaining health data that is amenable for collection from large heterogeneous populations in a real -world setting can help speed up validation of geroprotective interventions. Further, we propose inclusion of quality of life (QoL) data as a biomarker of aging and candidate endpoint for geroscience clinical trials to aid in distinguishing healthy from unhealthy aging. We highlight how QoL assays can aid in accelerating data collection in studies gathering RWE on the geroprotective effects of repurposed drugs to support utilization within healthy longevity medicine. Finally, we summarize key metrics to consider when implementing QoL assays in studies, and present the short -form 36 (SF -36) as the most well-suited candidate endpoint.
Ciprofol, a novel intravenous general anesthetic with a chemical structure similar to propofol, exhibits significantly enhanced potency. It offers a rapid onset, reduced incidence of injection pain, and has comparable effects on heart rate and blood pressure to propofol. However, clinical data on its use for anesthesia induction in cardiac surgery remain limited. Seventy-eight patients undergoing coronary artery bypass grafting or valve replacement surgery were randomly assigned to receive either ciprofol (N = 40) or propofol (N = 38) for anesthesia induction. Variables recorded included changes in mean arterial pressure and heart rate during anesthesia, alterations in the oxygenation index and lactic acid concentration before and 10 min after anesthesia induction, and the incidence of adverse events such as bradycardia, hypotension, and injection pain. The incidence of anesthesia-induced injection pain was significantly lower in the ciprofol group compared to the propofol group (3% vs. 18%, P < 0.05). The incidence of other adverse events was similar between the groups. No significant differences in hemodynamics or oxygenation index were observed during anesthesia induction between ciprofol and propofol. Ciprofol demonstrated a significantly lower incidence of injection pain compared to propofol, potentially improving patient comfort during anesthesia induction. Additionally, ciprofol showed comparable circulatory stability to propofol during anesthesia induction in cardiac surgery, suggesting it may be a suitable alternative to propofol for this application. The trial was registered at the ClinicalTrials.gov on 03/10/2024 (NCT06312345).